World Health Organization Group III pulmonary hypertension

Hooman D. Poor, Reda Girgis, Sean M. Studer

Research output: Contribution to journalArticle


Pulmonary hypertension in the setting of parenchymal lung disease and conditions associated with chronic hypoxemia is commonly encountered in clinical practice and may adversely affect patients' function and mortality. Diagnosis of this subgroup of pulmonary hypertension has evolved but still requires right heart catheterization for confirmation. The primary treatment goal is optimization of the underlying parenchymal lung or hypoxemia-associated condition prior to consideration of pharmacologic therapy. Limited published experience with pulmonary hypertension-specific medications for treatment of WHO Group 3 pulmonary hypertension suggests symptomatic and functional benefit in selected individuals. The potential for worsening ventilation-perfusion matching must be considered in these cases, however, since there is a paucity of data regarding the optimal approach to treatment selection. Ongoing medication trials and further investigation of mechanisms of hypoxic pulmonary vasoconstriction provide hope for these patients who in the past often had only lung transplantation as a potential treatment option.

Original languageEnglish (US)
Pages (from-to)119-127
Number of pages9
JournalProgress in Cardiovascular Diseases
Issue number2
Publication statusPublished - Sep 2012
Externally publishedYes



  • COPD
  • Hypoxic pulmonary vasoconstriction
  • ILD
  • OSA
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this